Stockreport

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc.  (BOLT) 
PDF –   BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones–   BDC-3042 Phase 1 study successfully cleared [Read more]